Muutke küpsiste eelistusi

E-raamat: Emerging Infectious Diseases: Clinical Case Studies

Edited by , Edited by (Professor of Infectious Diseases and Clinical Microbiology, Koc University School of Medicine, Istanbul, Turkey), Edited by (Attending Physician in the Infe), Edited by (Associate professor of medical microbiology at the Koc University School of Medicine)
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 128,31 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Emerging Infectious Diseases: Clinical Case StudiesSuurem pilt
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

More than 30 newly emerged microorganisms and related diseases have been discovered in the past 20 years. Since these infections are so new, even infectious diseases experts and clinical microbiologists need more information. This book covers recently emerged infectious diseases based on real cases and provides comprehensive information including different aspects of the infections. Written in a ‘teaching’ style, this book is of interest to every medical specialist and student.

  • Includes more than 35 emerging infection cases based on the following criteria:
    newly emerged or re-emerged
    recently acquired significance in clinical practice
    recently radically changed in case management
  • Offers a balanced synthesis of basic and clinical sciences for each individual case, presenting clinical courses of the cases in parallel with the pathogenesis and detailed microbiological information for each infection
  • Describes the prevalence and incidence of the global issues and current therapeutic approaches
  • Presents the measures for infection control

Arvustused

"...an easy-to-use, extraordinarily informative text that belongs on every clinicians shelfit highlights areas where there are gaps in our knowledge...an apropos read for any clinician who carries a pager." --Clinical Infectious Diseases"...a comprehensive review of both new and old infectious diseases, primarily endemic diseases that occur in specific geographic areas of the world...a reference that should be readily available in medical libraries throughout the world. Rating: 78 - 3 Stars" --Doody's.com, 2015

Muu info

Presents clinical case studies in parallel with the pathogenesis and provides detailed microbiological information on each emerging infection
List of Contributors
xxi
Preface xxv
1 Severe Fever with Thrombocytopenia Syndrome Associated with a Novel Bunyavirus
Keita Matsuno
Heinz Feldmann
Hideki Ebihara
1 Why this Case was Significantly Important as an Emerging Infection
2(1)
2 What is the Causative Agent?
2(1)
3 What is the Frequency of the Disease in Endemic Regions?
3(1)
4 How is the Virus Transmitted?
4(1)
5 What are the Clinical Manifestations of the Disease?
5(2)
6 What are the Mechanisms of Pathogenesis?
7(1)
7 How do you Diagnose the Infection?
8(1)
8 How do you Differentiate the Infection from Similar Clinical Manifestations?
9(1)
9 What are the Therapeutic Approaches?
9(1)
10 What are the Preventive and Infection Control Measures?
9(6)
Acknowledgments
10(1)
References
10(5)
2 Bas-Congo Virus: A Novel Rhabdovirus Associated with Acute Hemorrhagic Fever
Gilda Grard
Joseph Fair
Charles Chiu
Eric Leroy
1 Why this Case was Significantly Important as an Emerging Infection
15(1)
2 What is the Causative Agent?
15(1)
2.1 BASV as the Etiologic Agent of an Acute Hemorrhagic Fever Syndrome
15(1)
2.2 BASV Taxonomy
15(1)
2.3 Virus Description
16(1)
3 What is the Frequency of the Disease?
16(2)
4 How is the Virus Transmitted?
18(2)
5 What are the Clinical Manifestations?
20(1)
6 How do you Diagnose?
20(1)
6.1 Molecular Diagnosis
20(1)
6.2 Viral Isolation
20(1)
6.3 Serologic Diagnosis
21(1)
7 How do you Differentiate this Disease from Similar Entities?
21(1)
8 What is the Therapeutic Approach?
21(2)
9 What are the Preventive and Infection Control Measures?
23(3)
References
23(3)
3 Hantavirus Infections
Tatjana Avsic Zupanc
Misa Korva
1 Why this Case was Significantly Important as an Emerging Infection
26(1)
2 What is the Causative Agent?
26(1)
3 What is the Frequency of the Disease?
27(1)
4 How is the Virus Transmitted?
28(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
29(1)
6 What are the Clinical Manifestations?
29(3)
7 How do you Diagnose?
32(1)
8 How do you Differentiate this Disease from Similar Entities?
33(1)
9 What is the Therapeutic Approach?
33(1)
10 What are the Preventive and Infection Control Measures?
33(6)
References
34(5)
4 Lassa Fever
Donald S. Grant
Humarr Khan
John Schieffelin
Daniel G. Bausch
1 Why Lassa Fever is Important as an Emerging Infection
39(1)
2 What is the Causative Agent?
39(1)
3 What is the Frequency of the Disease?
39(6)
4 How is the Virus Transmitted?
45(2)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
47(1)
6 What are the Clinical Manifestations?
47(3)
7 How do you Make the Diagnosis?
50(1)
8 How do you Differentiate this Disease from Similar Entities?
50(4)
9 What is the Therapeutic Approach?
54(1)
10 What are the Preventive and Infection Control Measures?
55(6)
References
56(5)
5 Alkhurma Hemorrhagic Fever
Pierre E. Rollin
Ziad A. Memish
1 Why this Case was Significantly Important as an Emerging Infection
61(1)
2 What is the Causative Agent?
62(1)
3 What is the Frequency of the Disease?
62(1)
4 How is the Virus Transmitted?
62(2)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
64(1)
6 What are the Clinical Manifestations?
64(1)
7 How do you Diagnose?
64(5)
7.1 Viral Isolation
68(1)
7.2 Molecular Detection: RT-PCR
68(1)
7.3 Serological Diagnosis
69(1)
8 How do you Differentiate this Disease from Similar Entities?
69(1)
9 What is the Therapeutic Approach?
69(1)
10 What are the Preventive and Infection Control Measures?
69(5)
References
70(4)
6 Rift Valley Fever
Janusz T. Paweska
1 Why RVF Outbreak was Important as an Emerging Infection
74(1)
2 What is the Causative Agent?
75(1)
3 What is the Burden and Geographic Distribution of RVF?
76(1)
4 How is RVFV Maintained and Transmitted?
77(3)
4.1 Vectors
77(1)
4.2 Virus Amplifiers
78(1)
4.3 Transmission to Humans
78(1)
4.4 Inter-Epizootic Period and Virus Geographic Spread
79(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
80(1)
6 What are RVF Clinical Manifestations?
81(1)
7 How Do You Diagnose?
82(2)
8 How Do You Differentiate this Disease from Similar Entities?
84(1)
9 What is the Therapeutic Approach?
84(1)
10 What are the Preventive and Infection Control Measures?
85(11)
10.1 Isolation Precaution
86(1)
10.2 Post-Exposure
86(1)
References
86(10)
7 Lujo Virus Hemorrhagic Fever
Janusz T. Paweska
1 Why this case was Significantly Important as an Emerging Infection
96(2)
2 What is the Causative Agent?
98(1)
3 What is the Frequency of the Disease?
99(1)
4 How is the Virus Transmitted?
99(1)
5 Which Factors are Involved in Disease Pathogenesis? what are the Pathogenic Mechanisms?
100(1)
6 What are LHF Clinical Manifestations?
101(2)
7 How do you Diagnose?
103(1)
8 How do you Differentiate this Disease from Similar Entities?
103(1)
9 What is the Therapeutic Approach?
104(1)
10 What are the Preventive and Infection Control Measures?
105(7)
10.1 Isolation Precautions
106(1)
10.2 Post-exposure Management
106(1)
References
107(5)
8 Toscana Virus Infection
Remi N. Charrel
1 Why this Case was Significantly Important as an Emerging Infection
112(1)
2 What is the Causative Agent?
113(1)
3 What is the Frequency of the Disease?
113(1)
4 How is the Virus Transmitted?
114(1)
5 Which Factors are Involved in Disease Pathogenesis? what are the Pathogenic Mechanisms?
115(1)
6 What are the Clinical Manifestations?
115(1)
7 How do you Diagnose?
115(1)
8 How do you Differentiate this Disease from Similar Entities?
116(1)
9 What is the Therapeutic Approach?
116(1)
10 What are the Preventive and Infection Control Measures?
116(8)
References
117(7)
9 Ebola Virus Disease
Pierre Formenty
1 Brief Justification on Why this Case was Identified as Emergent
124(1)
2 What is the Causative Agent?
124(1)
3 What is the Frequency of the Disease?
125(1)
4 What are the Transmission Routes?
125(3)
4.1 Reported Routes of Transmission
125(2)
4.2 Possible Other Routes of Transmission
127(1)
5 What are the Clinical Manifestations?
128(1)
6 How do you Diagnose?
128(1)
7 How do you Differentiate this Disease from Similar Entities?
129(1)
8 What is the Therapeutic Approach?
129(1)
9 What are the Preventive and Infection Control Measures?
130(6)
9.1 Preventive Measures
130(2)
9.2 Infection Control Measures
132(1)
References
132(4)
10 Crimean-Congo Hemorrhagic Fever
Onder Ergonul
1 Why this Case was Significantly Important as an Emerging Infection
136(1)
2 What is the Causative Agent?
136(1)
3 What is the Frequency of the Disease?
137(1)
4 How is the Virus Transmitted?
137(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
138(1)
6 What are the Clinical Manifestations?
139(1)
7 How do you Diagnose?
140(3)
7.1 Viral Isolation
140(1)
7.2 Molecular Detection: RT-PCR
141(1)
7.3 Indirect Serological Diagnosis
141(2)
8 How do you Differentiate this Disease from Similar Entities?
143(1)
9 What is the Therapeutic Approach?
143(2)
10 What are the Preventive and Infection Control Measures?
145(5)
10.1 Isolation Precautions
145(1)
10.2 Post-exposure Management
145(1)
References
146(4)
11 Phlebotomus Fever---Sandfly Fever
Koray Ergunay
1 Why this Case was Significantly Important as an Emerging Infection
150(1)
2 What is the Causative Agent?
150(1)
3 What is the Frequency of the Disease?
151(1)
4 How is the Virus Transmitted?
152(2)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
154(1)
6 What are the Clinical Manifestations?
154(2)
7 How do you Diagnose?
156(1)
8 How do you Differentiate this Disease from Similar Entities?
157(1)
9 What is the Therapeutic Approach?
157(1)
10 What are the Preventive and Infection Control Measures?
158(6)
References
158(6)
12 Chikungunya Fever
Giovanni Rezza
1 Why this Case was Significantly Important as an Emerging Infection
164(1)
2 What is the Causative Agent?
164(1)
3 What is the Frequency of the Disease?
165(1)
4 How is the Virus Transmitted?
166(2)
5 Which Factors are Involved in Disease Pathogenesis? What is the Pathogenic Mechanism?
168(1)
6 What are the Clinical Manifestations?
169(1)
7 How do you Diagnose?
169(1)
8 How do you Differentiate this Disease from Similar Entities?
170(1)
9 What is the Therapeutic Approach?
170(1)
10 What are the Preventive and Infection Control Measures?
171(5)
References
173(3)
13 Nipah Virus Disease
Pierre E. Rollin
1 Why this Case was Significantly Important as an Emerging Infection?
176(1)
2 What is the Causative Agent?
176(1)
3 What is the Frequency of the Disease in your Region?
176(1)
4 How is the Virus Transmitted?
177(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
178(1)
6 What are the Clinical Manifestations?
178(2)
7 How do you Make the Diagnosis?
180(1)
7.1 Viral Isolation
180(1)
7.2 Molecular Detection: RT-PCR
180(1)
7.3 Immunohistochemistry
181(1)
7.4 Serological Diagnosis
181(1)
8 How do you Differentiate this Disease from similar entities?
181(1)
9 What is the Therapeutic Approach?
182(1)
10 What are the Preventive and Infection Control Measures?
182(4)
References
182(4)
14 Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
Jaffar A. Al-Tawfiq
Ziad A. Memish
1 What is the Causative Agent?
186(1)
2 What is the Frequency of the Disease? Prevalence, Incidence, Burden, and impact of the Disease
186(1)
3 What are the Transmission Routes?
187(1)
4 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
187(1)
5 What are the Clinical Manifestations?
187(1)
6 How do you Diagnose?
188(1)
7 How do you Differentiate this Disease from Similar Entities?
188(1)
8 What is the Therapeutic Approach?
188(1)
9 What are the Preventive and Infection Control Measures
188(4)
References
189(3)
15 Human Bocavirus
Tina Ursic
Miroslav Petrovec
1 Why this Case was Significantly Important as an Emerging Infection
192(1)
2 What is the Causative Agent?
192(1)
3 What is the Frequency of the Disease?
193(1)
4 How is the Virus Transmitted?
193(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
194(2)
6 What are the Clinical Manifestations?
196(1)
7 How do you Diagnose?
196(1)
7.1 Molecular Detection: PCR
196(1)
7.2 Serological Diagnosis: ELISA
196(1)
8 How do you Differentiate the Disease from Similar Entities?
197(1)
9 What is the Therapeutic Approach?
197(1)
10 What are the Preventive and Infection Control Measures?
197(7)
References
198(6)
16 Norovirus Gastroenteritis
Momoko Mawatari
Yasuyuki Kato
1 Why this Case was Significantly Important as an Emerging Infection
204(1)
2 What is the Causative Agent?
204(1)
3 What is the Frequency of the Disease?
204(1)
4 How is the Virus Transmitted?
204(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
205(1)
6 What are the Clinical Manifestations?
206(1)
7 How do you Diagnose?
206(1)
8 How do you Differentiate this Disease from Similar Entities?
207(1)
9 What is the Therapeutic Approach?
208(1)
10 What are the Preventive and Infection Control Measures
208(5)
References
209(4)
17 Enterohemorrhagic Escherichia coli (EHEC): Hemorrhagic Colitis and Hemolytic Uremic Syndrome (HUS)
Jakob P. Cramer
1 Why this Case was Significantly Important as an Emerging Infection
213(1)
2 What is the Causative Agent?
214(1)
3 What is the Frequency of the Disease?
215(1)
4 How are EHEC Transmitted?
215(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
216(1)
6 What are the Clinical Manifestations?
217(2)
7 How is the Disease Diagnosed?
219(1)
8 How do you Differentiate this Disease from Similar Entities?
220(1)
9 What is the Therapeutic Approach?
221(1)
10 What are the Preventive and Infection Control Measures?
222(9)
References
223(8)
18 Emerging Clostridium difficile Infections
Itaru Nakamura
Yasutaka Mizuno
1 Why this Case was Significantly Important as an Emerging Infection
231(1)
2 What is the Causative Agent?
231(1)
3 What is the Frequency of the Disease?
232(1)
4 How are the Bacteria Transmitted?
232(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
233(1)
6 What are the Clinical Manifestations?
233(1)
7 How do you Diagnose?
234(1)
8 How do you Differentiate this Disease from Similar Entities?
235(1)
9 What is the Therapeutic Approach?
235(1)
10 What are the Preventive and Infection Control Measures?
236(4)
References
236(4)
19 Multidrug-Resistant Tuberculosis
Jan Heyckendorf
Christoph Lange
Julia Martensen
1 Why this Case was Significantly Important as an Emerging Infection
240(1)
2 What is the Causative Agent?
241(1)
3 What is the Frequency of the Disease?
241(1)
4 How are the Bacteria Transmitted?
242(2)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenetic Mechanisms?
244(1)
6 What are the Clinical Manifestations?
244(1)
7 How do you Diagnose?
245(3)
8 How do You Differentiate this Disease from Similar Entities?
248(1)
9 What is the Therapeutic Approach?
248(3)
10 What are the Preventive and Infection Control Measures?
251(5)
References
251(5)
20 Acinetobacter Infections
Nicola Petrosillo
Cecilia Melina Drapeau
Stefano Di Bella
1 Why this Case was Significantly Important as an Emerging Infection
256(1)
2 What is the Causative Agent?
256(1)
3 What is the Frequency of the Disease?
257(1)
4 How are the Bacteria Transmitted?
258(2)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
260(1)
6 What are the Clinical Manifestations?
261(2)
6.1 Nosocomial Infections
261(1)
6.2 Community-Acquired Infections
262(1)
7 How do you Diagnose?
263(1)
8 How do you Differentiate this Disease from Similar Entities?
263(1)
9 What is the Therapeutic Approach?
264(2)
9.1 Carbapenems
264(1)
9.2 Sulbactam
264(1)
9.3 Colistin
264(1)
9.4 Tigecycline
265(1)
9.5 Aminoglycosides
265(1)
9.6 Combination Therapy
265(1)
10 What are the Preventive and Infection Control Measures?
266(9)
References
267(8)
21 Infections Due to NDM-1 Producers
Patrice Nordmann
Laurent Dortet
Laurent Poirel
1 Why was this Case Identified as Emergent?
275(1)
2 What is the Causative Agent?
275(1)
3 What is the Frequency of the Disease? (Prevalence, Incidence, Burden, and Impact of the Disease)
276(2)
4 What are the Transmission Routes?
278(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
278(1)
6 What are the Clinical Manifestations?
279(1)
7 How do you Diagnose?
279(6)
7.1 Diagnosis of Infected Patients
280(2)
7.2 Identification of Carriers
282(3)
8 How do you Differentiate this Disease from Similar Entities?
285(1)
9 What is the Therapeutic Approach?
285(1)
10 What are the Preventive and Infection Control Measures?
286(1)
11 Conclusion
287(9)
References
287(9)
22 The Exserohilum rostratum Incident: The Compounding Pharmacy as a Source of Emerging Infections
Larry Lutwick
1 Why this Case was Significantly Important as an Emerging Infection
296(1)
2 What is the Causative Agent?
297(1)
3 What is the Frequency of the Disease?
298(1)
4 How are the Fungi Transmitted?
298(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
299(1)
6 What are the Clinical Manifestations?
300(1)
6.1 Probable Case
300(1)
6.2 Confirmed Case
300(1)
7 How do you Diagnose?
300(2)
7.1 Imaging Studies
300(1)
7.2 Culture
301(1)
7.3 PCR
302(1)
7.4 Fungal Antigens
302(1)
8 How do you Differentiate this Disease from Similar Entities?
302(1)
9 What is the Therapeutic Approach?
302(2)
9.1 CNS
302(1)
9.2 Bone and Joint
303(1)
9.3 Other Treatment Considerations
303(1)
10 What are the Preventive and Infection Control Measures?
304(6)
References
305(5)
23 Mucormycosis
M. Bulent Ertugrul
Sevtap Arikan-Akdagli
1 Why this Case was Significantly Important as an Emerging Infection
310(1)
2 What is the Causative Agent?
310(1)
3 What is the Frequency of the Disease?
311(1)
4 What are the Transmission Routes?
311(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
312(1)
6 What are the Clinical Manifestations?
312(3)
6.1 Rhinocerebral Mucormycosis
313(1)
6.2 Pulmonary Mucormycosis
313(1)
6.3 Cutaneous Mucormycosis
314(1)
6.4 Gastrointestinal Mucormycosis
314(1)
6.5 Disseminated Mucormycosis
315(1)
7 How do you Diagnose?
315(2)
7.1 Histopathology
315(1)
7.2 Culture
316(1)
7.3 Molecular Diagnosis
317(1)
8 How do you Differentiate this Disease from Similar Entities?
317(1)
9 What is the Therapeutic Approach?
318(1)
10 What are the Preventive and Infection Control Measures?
318(6)
References
319(5)
24 Lyme Borreliosis
Dasa Stupica
Gerold Stanek
Franc Strle
1 Why this Case was Significantly Important as an Emerging Infection
324(1)
2 What is the Causative Agent?
324(1)
3 What is the Frequency of the Disease?
324(1)
4 How are These Bacteria Transmitted?
325(1)
5 What are the Pathogenic Mechanisms?
325(1)
6 What are the Clinical Manifestations?
326(4)
6.1 Skin
326(3)
6.2 Nervous System
329(1)
6.3 Heart
329(1)
6.4 Joints
329(1)
6.5 Eyes
330(1)
6.6 Other Rare Manifestations
330(1)
6.7 Non-Specific Symptoms
330(1)
7 How do you Diagnose?
330(2)
8 How do you Differentiate this Disease from Similar Entities?
332(1)
9 What is the Therapeutic Approach?
332(1)
10 What are the Preventive and Infection Control Measures?
333(5)
References
333(5)
25 Plasmodium knowlesi
Jana Preis
Larry Lutwick
1 Why this Case was Significantly Important as an Emerging Infection
338(1)
2 What is the Causative Agent?
338(1)
3 What is the Frequency of the Disease/Epidemiology?
338(1)
4 How is the Parasite Transmitted?
339(1)
5 What Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
340(1)
6 What are the Clinical Manifestations?
340(2)
7 How do you Diagnose?
342(1)
8 How do you Differentiate this Disease from Similar Entities?
342(1)
9 What is the Therapeutic Approach?
343(1)
10 What are the Preventive and Infection Control Measures?
344(4)
References
344(4)
26 Measles
Alpay Azap
Filiz Pehlivanoglu
1 Brief Justification on Why this Case was Identified as Emergent
348(1)
2 What is the Causative Agent? (Taxonomy and Description of the Agent)
348(1)
3 What is the Frequency of the Disease? (Prevalence, Incidence, Burden, and Impact of the Disease)
349(1)
4 What are the Transmission Routes?
349(1)
5 Which Factors are Involved in Disease Pathogenesis? What is the Pathogenic Mechanism?
350(1)
6 What are the Clinical Manifestations?
350(2)
6.1 Modified Measles
352(1)
6.2 Atypical Measles
352(1)
7 How do you Diagnose?
352(1)
8 How do you Differentiate this Disease from Similar Entities?
353(1)
9 What is the Therapeutic Approach?
354(1)
10 What are the Preventive and Infection Control Measures?
354(6)
10.1 Prevention
354(1)
10.2 Infection Control Measures
355(1)
10.3 Managing Patients with Measles
355(1)
10.4 Managing the Infection Control among Healthcare Workers
356(1)
10.5 Managing Non-Immune Exposed Patients
356(1)
References
357(3)
27 Pertussis
Larry Lutwick
Jana Preis
1 Brief Justification on Why this Case was Identified as Emergent
360(1)
2 What is the Causative Agent?
360(1)
3 What is the Frequency of the Disease?
361(1)
4 How are the Bacteria Transmitted?
362(1)
4.1 Household
362(1)
4.2 Nosocomial
362(1)
5 Which Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
363(1)
6 What are the Clinical Manifestations?
364(1)
7 How do you Diagnose?
365(1)
7.1 Culture
366(1)
7.2 PCR
366(1)
8 How do you Differentiate this Disease from Similar Entities?
366(1)
9 What is the Therapeutic Approach?
367(1)
10 What are the Preventive and Infection Control Measures?
368(6)
References
369(5)
28 Buruli Ulcer (Atypical Mycobacteria)
Dr. Gene Khai Lin Huang
Dr. Paul Johnson
1 Why this Case was Significantly Important as an Emerging Infection
374(1)
2 What is the Causative Agent?
375(1)
3 What is the Frequency of the Disease?
375(1)
4 How are the Bacteria Transmitted?
376(1)
5 What Factors are Involved in Disease Pathogenesis? What are the Pathogenic Mechanisms?
377(1)
6 What are the Clinical Manifestations?
378(1)
7 How do you Diagnose?
378(1)
8 How do you Differentiate this Disease from Similar Entities?
379(1)
9 What is the Therapeutic Approach?
379(1)
10 What are the Preventive and Infection Control Measures?
380(5)
References
381(4)
Index 385
Onder Ergonul, MD, MPH has been a professor of Infectious Diseases and Clinical Microbiology at Koç University, School of Medicine since 2011. He graduated from Hacettepe University School of Medicine in 1989 and completed his residency in 1996 in the Infectious Diseases and Clinical Microbiology department of Ankara University in Ankara, Turkey. He received his Master of Public Health degree from Harvard University School of Public Health in 2003. In 2000-2002, he worked as a research fellow in the Clinical Epidemiology division of the Infectious Diseases Department at the University of Utah, School of Medicine, USA. He is the editor of a book on Crimean-Congo Hemorrhagic Fever (2007, Springer). He received the Public Health Scientific award of Turkish Medical Association in 2007. He has been the president of the Turkish Society of Clinical Microbiology and Infectious Diseases since 2013. He has been the associate editor of Clinical Microbiology and Infection, official journal of the European Society of Clinical Microbiology and Infectious Diseases since 2013. He was elected as the member of Science Academy of Turkey in 2013. Fusun Can, MD Can is an associate professor of medical microbiology at the Koc University School of Medicine. She is specialized in the epidemiology of emerging bacterial pathogens, antibiotic resistance mechanisms and biofilm related infections. She graduated from Hacettepe University School of Medicine in 1989 and completed her residency in 1996 at Ankara University, Department of Microbiology and Clinical Microbiology in Ankara,Turkey. She worked as a research fellow in the Department of Microbiology at the University of Florida School of Medicine, USA. Before joining Koc University, she was the director of the Department of Medical Microbiology at Baskent University, in Ankara. She is responsible for the Microbiology and Biosafety Level III Laboratory at Koc University. Murat Akova, MD is a graduate of Istanbul University Medical School. He completed his residency training in internal medicine at Hacettepe University School of Medicine in Ankara in 1988 and in infectious diseases in 1991. Dr. Akova studied at the Department of Medical Microbiology in London Hospital Medical College, London, UK between 1988-1989 and obtained an DSc Degree in Clinical Microbiology from this institution. He was a visiting scientist at the Center for Adaptive Resistance and Microbiology in Tufts University School of Medicine, Boston, USA between 1992-1993. Currently, he serves as an attending physician in the Infectious Diseases Department at Hacettepe University School of Medicine. Dr. Akova is a member of the Executive Committee of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and his current function is the General Secretary and Scientific Affairs Officer. He is the president-elect of ESCMID from 2014-2016. Among his scientific research interests are infections in immunocompromised host and antimicrobial resistance. Lawrence C. Madoff, MD is an academic infectious disease physician specializing in the epidemiology of emerging pathogens, bacterial pathogenesis, and international health. He is Professor of Medicine at the University of Massachusetts Medical School and is on the attending staff at the University of Massachusetts Memorial Medical Center. Dr. Madoff serves as Director of Epidemiology and Immunization, Deputy State Epidemiologist and Interim Director of the Hinton State Laboratory Institute for the Massachusetts Department of Public Health. Dr. Madoff has been the Editor of ProMED, the Program for Monitoring Emerging Diseases, since 2002. He is a member of the American Society for Microbiology, the International Society for Infectious Diseases, past President of the U.S. Lancefield Streptococcal Research Society, a Fellow of the Infectious Diseases Society of America and a Fellow of the American College of Physicians. A graduate of Yale College and Tufts Medical School, he performed his Internal Medicine Residency at New York Hospital-Cornell Medical Center and his Infectious Disease Fellowship at the Harvard Medical School-Longwood program. He is the author of over 100 scientific and medical publications including original research papers, reviews, editorials and book chapters on topics involving infectious diseases and microbiology.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97801242010956e.html
Märksõnad: